Literature DB >> 9674872

Predictive factors of tumor response and prognostic factors of survival during lung cancer chemotherapy.

P Ray1, X Quantin, J Grenìer, J L Pujol.   

Abstract

The aim of this study was (i) to determine predictive factors of a complete response to chemotherapy in small cell lung cancer (SCLC) and predictive factors of an objective response in non-small cell lung cancer (NSCLC) and (ii) to determine whether prognostic factors are different with regard to treatment response and survival. Ninety-nine patients with SCLC and two hundred and two patients with NSCLC received chemotherapy. The following variables were recorded prior to treatment: tumor, node, metastasis status, performance status, body weight loss, blood leukocyte count, serum sodium, serum albumin, lactate dehydrogenase (LDH), alkaline phosphatase, serum NSE, serum TPS, and serum CYFRA 21-1. Tumor response was analyzed at the 10th week. Analysis of survival were done using the landmark method. Hazard ratios of the significant prognostic variables of survival were calculated using the Cox's model. Odds ratios of the significant predicting factors of response were calculated by stepwise logistic regression. In SCLC, the significant determinants of poor survival were: lack of complete response (HR: 2.04), weight loss (HR: 1.76), high serum LDH level (HR: 1.64), and high serum TPS level (HR: 2.47). A high serum TPS level was the only factor among those studied able to predict lack of achievement of complete response (OR: 0.39). In NSCLC, significant determinants of poor survival were: no objective response (HR: 2.28), poor performance status (HR: 2.52), presence of metastases (HR: 1.51), and high serum CYFRA 21-1 level (HR: 1.84). On the other hand, a high serum TPS level (OR: 0.50), the presence of metastases (OR: 0.45), and a leukocyte blood count over 10,000/microl (OR: 0.43) were independent determinants for a patient not to achieve an objective response. We concluded that the predictive factors of complete response in SCLC remain to be defined. On the other hand, in NSCLC three variables contribute to the prediction of an objective response. Finally, determinants of survival differ from predictive factors of response.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9674872     DOI: 10.1046/j.1525-1500.1998.cdoa43.x

Source DB:  PubMed          Journal:  Cancer Detect Prev        ISSN: 0361-090X


  8 in total

1.  Serum lactate dehydrogenase levels at presentation in stage IV non-small cell lung cancer: predictive value of metastases and relation to survival outcomes.

Authors:  Dong Soo Lee; Kyung Ran Park; Seung Joon Kim; Mi Joo Chung; Yun Hee Lee; Ji Hyun Chang; Jin Hyoung Kang; Sook Hee Hong; Myung Sin Kim; Yeon Sil Kim
Journal:  Tumour Biol       Date:  2015-08-04

Review 2.  Diagnosis and management of hyponatremia in cancer patients.

Authors:  Jorge J Castillo; Marc Vincent; Eric Justice
Journal:  Oncologist       Date:  2012-05-22

Review 3.  Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature.

Authors:  Digant Gupta; Christopher G Lis
Journal:  Nutr J       Date:  2010-12-22       Impact factor: 3.271

4.  A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB-IIIA resectable NSCLC.

Authors:  John P Crandall; Abdel K Tahari; Rosalyn A Juergens; Julie R Brahmer; Charles M Rudin; Giuseppe Esposito; Deepa S Subramaniam; Michael V Knopp; Nathan C Hall; Prateek Gajwani; Jeffrey P Leal; Martin A Lodge; Joo H O; Edward W Gabrielson; Lalitha K Shankar; Richard L Wahl
Journal:  EJNMMI Res       Date:  2017-01-19       Impact factor: 3.138

5.  Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials.

Authors:  Richard J Gralla; Fatima Ahmad; Jaime D Blais; Joseph Chiodo; Wen Zhou; Linda A Glaser; Frank S Czerwiec
Journal:  Cancer Med       Date:  2017-03-02       Impact factor: 4.452

6.  Prognostic implication of erector spinae muscles in non-small-cell lung cancer patients treated with immuno-oncology combinatorial chemotherapy.

Authors:  Taisuke Araki; Yoshiaki Kitaguchi; Yusuke Suzuki; Masamichi Komatsu; Kei Sonehara; Yosuke Wada; Kazunari Tateishi; Masayuki Hanaoka
Journal:  Thorac Cancer       Date:  2021-10-02       Impact factor: 3.500

7.  Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer.

Authors:  S Negoro; N Masuda; Y Takada; T Sugiura; S Kudoh; N Katakami; Y Ariyoshi; Y Ohashi; H Niitani; M Fukuoka
Journal:  Br J Cancer       Date:  2003-02-10       Impact factor: 7.640

8.  Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?

Authors:  P J Ross; S Ashley; A Norton; K Priest; J S Waters; T Eisen; I E Smith; M E R O'Brien
Journal:  Br J Cancer       Date:  2004-05-17       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.